share_log

Tonix Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Tonix Pharmaceuticals | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/13 06:14

Moomoo AI 已提取核心信息

Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.
Tonix Pharmaceuticals reported Q3 2024 financial results with net revenue of $2.8 million and a net loss of $14.2 million, compared to revenue of $4.0 million and a net loss of $28.0 million in Q3 2023. Research and development expenses decreased 57% to $9.1 million, while selling, general and administrative expenses declined 11% to $7.7 million. The company recorded $1.7 million in grant income during the quarter.The company's cash position stood at $28.2 million as of September 30, 2024. During Q3, Tonix raised approximately $41.8 million through ATM offerings and an additional $3.5 million through a securities purchase agreement. The company expects current cash resources to fund operations into Q1 2025 but will require additional financing to continue operations beyond that point.Tonix's lead program TNX-102 SL for fibromyalgia received FDA Fast Track designation in Q3 2024, with an NDA submitted in October 2024. The company expects an FDA decision on NDA acceptance and PDUFA date in December 2024. Additionally, Tonix secured a DTRA contract worth up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent targeting CD45.
Tonix Pharmaceuticals发布了2024年第三季度的财务业绩，净营业收入为280万美元，净亏损为1420万美元，而2023年第三季度的营业收入为400万美元，净亏损为2800万美元。研发费用减少了57%，降至910万美元，而销售、一般和行政费用下降了11%，降至770万美元。该公司在本季度记录了170万美元的拨款收入。截至2024年9月30日，该公司的现金状况为2820万美元。在第三季度，Tonix通过ATm发行筹集了约4180万美元，并通过证券购买协议额外筹集了350万美元。公司预计当前现金资源将支持运营到2025年第一季度，但需要额外融资以继续维持运营。Tonix在2024...展开全部
Tonix Pharmaceuticals发布了2024年第三季度的财务业绩，净营业收入为280万美元，净亏损为1420万美元，而2023年第三季度的营业收入为400万美元，净亏损为2800万美元。研发费用减少了57%，降至910万美元，而销售、一般和行政费用下降了11%，降至770万美元。该公司在本季度记录了170万美元的拨款收入。截至2024年9月30日，该公司的现金状况为2820万美元。在第三季度，Tonix通过ATm发行筹集了约4180万美元，并通过证券购买协议额外筹集了350万美元。公司预计当前现金资源将支持运营到2025年第一季度，但需要额外融资以继续维持运营。Tonix在2024年第三季度的领先项目TNX-102 SL针对纤维肌痛症获得了FDA快速通道认证，NDA已于2024年10月提交。公司预计FDA将在2024年12月就NDA的接受和PDUFA日期做出决定。此外，Tonix获得了一份价值高达3400万美元的DTRA合同，合同期为五年，用于开发TNX-4200，这是一种针对CD45的广谱抗病毒药物。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Conduit Pharmaceuticals
    CDT
    -- 0.123
    Unity Biotechnology
    UBX
    -- 1.7900
    Radiopharm Theranostics
    RADX
    -- 5.350
    DBV Technologies
    DBVT
    -- 4.970
    NRX Pharmaceuticals
    NRXP
    -- 4.8500

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    特朗普即将重返政治舞台！特朗普提出的“美国优先”关税政策、加密货币政策以及对科技行业的影响，已成为市场关注的焦点。在此背景下，crypto、Tesla、AI板块的未来走势值得关注。 🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    询问策略师 - 川普的首日
    查看更多